Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
2(20%)
Results Posted
25%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
1
10%
Ph phase_2
2
20%
Ph phase_4
3
30%
Ph phase_3
3
30%

Phase Distribution

1

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
3(33.3%)
Phase 4Post-market surveillance
3(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(4)
Terminated(3)
Other(1)

Detailed Status

Completed4
Withdrawn2
Recruiting2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 22 (22.2%)
Phase 33 (33.3%)
Phase 43 (33.3%)

Trials by Status

unknown110%
terminated110%
withdrawn220%
completed440%
recruiting220%

Recent Activity

2 active trials
Showing 5 of 10
recruitingphase_4

Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia

NCT07511257
recruitingphase_4

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

NCT06187311
completedphase_3

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI

NCT05705089
completed

The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM

NCT05669313
withdrawnphase_3

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority

NCT02832531
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07511257Phase 4

Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia

Recruiting
NCT06187311Phase 4

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

Recruiting
NCT05705089Phase 3

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI

Completed
NCT05669313

The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM

Completed
NCT02832531Phase 3

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority

Withdrawn
NCT05233124Phase 2

Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia

Unknown
NCT03566303Phase 2

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis

Terminated
NCT03673605Phase 4

Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin

Withdrawn
NCT01830543Phase 3

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Completed
NCT02289703Phase 1

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10